- Gilead's Q4 2015 earnings offered a new perspective on the timeline for Gilead stock's fully recovery.
- Gilead's accelerated $5 billion share buyback program will significantly increase EPS, ROA & ROE. This will be a catalyst for a stellar Q1 2016 performance.
- Gilead has only reached ~13% of the market. Because AbbVie is losing ground, I believe there is more than enough room for Merck's Zepatier without hurting Gilead's bottom line.